Concepts (91)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchoscopy | 3 | 2019 | 35 | 0.640 |
Why?
|
| Pulmonary Alveolar Proteinosis | 1 | 2019 | 1 | 0.620 |
Why?
|
| Pandemics | 1 | 2021 | 199 | 0.600 |
Why?
|
| Castleman Disease | 1 | 2016 | 2 | 0.490 |
Why?
|
| Mediastinal Diseases | 1 | 2016 | 2 | 0.490 |
Why?
|
| Mediastinal Neoplasms | 1 | 2016 | 11 | 0.490 |
Why?
|
| Ear, Middle | 1 | 2016 | 40 | 0.470 |
Why?
|
| Bronchi | 2 | 2016 | 38 | 0.430 |
Why?
|
| Sneezing | 1 | 2014 | 2 | 0.420 |
Why?
|
| Subcutaneous Emphysema | 1 | 2014 | 4 | 0.420 |
Why?
|
| Hernia | 1 | 2014 | 9 | 0.420 |
Why?
|
| Hemorrhage | 1 | 2016 | 266 | 0.420 |
Why?
|
| Pneumothorax | 1 | 2014 | 15 | 0.420 |
Why?
|
| Lung Diseases | 1 | 2014 | 43 | 0.400 |
Why?
|
| Pulmonary Atelectasis | 1 | 2012 | 5 | 0.370 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2012 | 13 | 0.370 |
Why?
|
| Deoxyribonuclease I | 1 | 2012 | 10 | 0.370 |
Why?
|
| Respiration, Artificial | 1 | 2012 | 42 | 0.360 |
Why?
|
| Histoplasmosis | 1 | 2009 | 10 | 0.320 |
Why?
|
| Trachea | 1 | 2009 | 43 | 0.310 |
Why?
|
| Lung | 2 | 2019 | 382 | 0.250 |
Why?
|
| Humans | 14 | 2024 | 28851 | 0.250 |
Why?
|
| Benzodiazepines | 1 | 2024 | 10 | 0.220 |
Why?
|
| Male | 8 | 2024 | 13921 | 0.210 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2024 | 41 | 0.210 |
Why?
|
| Pulmonary Medicine | 1 | 2022 | 5 | 0.190 |
Why?
|
| Hypertension, Pulmonary | 1 | 2022 | 34 | 0.180 |
Why?
|
| Bronchial Diseases | 1 | 2021 | 5 | 0.180 |
Why?
|
| Tracheal Stenosis | 1 | 2021 | 7 | 0.180 |
Why?
|
| Personal Protective Equipment | 1 | 2021 | 14 | 0.170 |
Why?
|
| Middle Aged | 6 | 2024 | 7414 | 0.160 |
Why?
|
| Aged | 5 | 2024 | 5598 | 0.160 |
Why?
|
| Equipment Design | 1 | 2021 | 218 | 0.160 |
Why?
|
| Feasibility Studies | 1 | 2021 | 222 | 0.160 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2019 | 6 | 0.160 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2016 | 42 | 0.120 |
Why?
|
| Cough | 1 | 2016 | 11 | 0.120 |
Why?
|
| Influenza, Human | 1 | 2016 | 92 | 0.120 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 78 | 0.110 |
Why?
|
| DNA Methylation | 1 | 2016 | 152 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 148 | 0.110 |
Why?
|
| Adult | 3 | 2024 | 8024 | 0.110 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 379 | 0.110 |
Why?
|
| United States | 1 | 2021 | 2222 | 0.110 |
Why?
|
| Epithelial Cells | 1 | 2016 | 265 | 0.110 |
Why?
|
| Spirometry | 1 | 2013 | 10 | 0.100 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2013 | 16 | 0.100 |
Why?
|
| Bronchodilator Agents | 1 | 2013 | 15 | 0.100 |
Why?
|
| Smoking | 1 | 2016 | 477 | 0.090 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2012 | 12 | 0.090 |
Why?
|
| Treatment Outcome | 2 | 2024 | 2426 | 0.090 |
Why?
|
| Neoplasms | 1 | 2021 | 874 | 0.090 |
Why?
|
| Sodium Chloride | 1 | 2012 | 67 | 0.090 |
Why?
|
| Radiography | 1 | 2012 | 203 | 0.090 |
Why?
|
| Critical Illness | 1 | 2012 | 66 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 536 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 481 | 0.090 |
Why?
|
| Double-Blind Method | 1 | 2012 | 422 | 0.080 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 416 | 0.080 |
Why?
|
| Oxygen | 1 | 2012 | 237 | 0.080 |
Why?
|
| Histoplasma | 1 | 2009 | 6 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2009 | 67 | 0.080 |
Why?
|
| Antifungal Agents | 1 | 2009 | 69 | 0.070 |
Why?
|
| Respiratory Mucosa | 1 | 2009 | 68 | 0.070 |
Why?
|
| Prospective Studies | 1 | 2012 | 1280 | 0.070 |
Why?
|
| Bronchial Neoplasms | 1 | 2008 | 4 | 0.070 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2008 | 134 | 0.060 |
Why?
|
| Female | 4 | 2024 | 15624 | 0.060 |
Why?
|
| Length of Stay | 1 | 2024 | 245 | 0.050 |
Why?
|
| Pulmonary Circulation | 1 | 2022 | 15 | 0.050 |
Why?
|
| Dyspnea | 1 | 2022 | 25 | 0.050 |
Why?
|
| Vascular Resistance | 1 | 2022 | 50 | 0.050 |
Why?
|
| Fluoroscopy | 1 | 2019 | 36 | 0.040 |
Why?
|
| Cold Temperature | 1 | 2019 | 35 | 0.040 |
Why?
|
| Ultrasonography, Interventional | 1 | 2019 | 40 | 0.040 |
Why?
|
| Biopsy | 1 | 2019 | 208 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2024 | 2635 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2016 | 28 | 0.030 |
Why?
|
| DNA Modification Methylases | 1 | 2016 | 14 | 0.030 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2016 | 17 | 0.030 |
Why?
|
| DEAD Box Protein 58 | 1 | 2016 | 18 | 0.030 |
Why?
|
| Interferon-beta | 1 | 2016 | 40 | 0.030 |
Why?
|
| Interferons | 1 | 2016 | 70 | 0.030 |
Why?
|
| Receptors, Immunologic | 1 | 2016 | 73 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2016 | 92 | 0.030 |
Why?
|
| Interleukins | 1 | 2016 | 112 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2016 | 251 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2016 | 668 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2016 | 1022 | 0.030 |
Why?
|
| Time Factors | 1 | 2016 | 1613 | 0.020 |
Why?
|
| Lymphoma, B-Cell | 1 | 2008 | 19 | 0.020 |
Why?
|